Literature DB >> 15649960

Risk of variant Creutzfeldt-Jakob disease in France.

Marc Chadeau-Hyam1, Annick Alpérovitch.   

Abstract

BACKGROUND: France has the second highest number of variant Creutzfeldt-Jakob disease (vCJD) cases worldwide. Imports of bovine carcasses from the UK probably constituted the main source of exposure of the French population to the bovine spongiform encephalopathy (BSE) agent. Meat products consumed whilst visiting the UK have also been considered as a possible source of exposure.
METHODS: We estimated the number of future vCJD cases in France using a simulation approach. Both the distribution of the vCJD incubation period and the age-dependent susceptibility to the BSE agent were estimated from UK data. The French epidemic was simulated by gender and birth-cohort from data on the infectivity of UK bovine tissues and simulations of the French consumption of infected beef products. We also used data on travel to the UK between 1980 and 1995.
RESULTS: We predicted 33 future cases of vCJD: 12 in the 1940-69 birth-cohort and 21 in the post-1969 birth-cohort. No case was predicted in the pre-1940 cohort. Based on our model, simulated vCJD cases occurred later in the older (1940-69) than in the younger cohort (post-1969). Age at onset was stable in the post-1969 cohort and increased in the older cohort. The model predicted a small excess of male patients. No case was attributed to travels in the UK.
CONCLUSIONS: This modelling confirms that a large vCJD epidemic in France is very unlikely. Since France (where 60% of the total British exports of bovine carcasses were exported) has been highly exposed to the BSE agent, our results are reassuring for most countries worldwide.

Entities:  

Mesh:

Year:  2005        PMID: 15649960     DOI: 10.1093/ije/dyh374

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  8 in total

1.  Blood transfusion and spread of variant Creutzfeldt-Jakob disease.

Authors:  Klaus Dietz; Günter Raddatz; Jonathan Wallis; Norbert Müller; Inga Zerr; Hans-Peter Duerr; Hans Lefèvre; Erhard Seifried; Johannes Löwer
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

2.  A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia.

Authors:  Michael B Coulthart; Michael D Geschwind; Shireen Qureshi; Nicolas Phielipp; Alex Demarsh; Joseph Y Abrams; Ermias Belay; Pierluigi Gambetti; Gerard H Jansen; Anthony E Lang; Lawrence B Schonberger
Journal:  Brain       Date:  2016-10       Impact factor: 13.501

3.  Variant Creutzfeldt-Jakob disease: French versus British.

Authors:  Wen-Quan Zou; Pierluigi Gambetti
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

Review 4.  Variant CJD. 18 years of research and surveillance.

Authors:  Abigail B Diack; Mark W Head; Sandra McCutcheon; Aileen Boyle; Richard Knight; James W Ironside; Jean C Manson; Robert G Will
Journal:  Prion       Date:  2014-11-01       Impact factor: 3.931

5.  Source of variant Creutzfeldt-Jakob disease outside United Kingdom.

Authors:  Pascual Sanchez-Juan; Simon N Cousens; Robert G Will; Cornelia M van Duijn
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

6.  Constant transmission properties of variant Creutzfeldt-Jakob disease in 5 countries.

Authors:  Abigail B Diack; Diane Ritchie; Matthew Bishop; Victoria Pinion; Jean-Philippe Brandel; Stephane Haik; Fabrizio Tagliavini; Cornelia Van Duijn; Ermias D Belay; Pierluigi Gambetti; Lawrence B Schonberger; Pedro Piccardo; Robert G Will; Jean C Manson
Journal:  Emerg Infect Dis       Date:  2012-10       Impact factor: 6.883

7.  Estimation of the exposure of the UK population to the bovine spongiform encephalopathy agent through dietary intake during the period 1980 to 1996.

Authors:  Chu-Chih Chen; Yin-Han Wang
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

Review 8.  Epidemiological characteristics of human prion diseases.

Authors:  Cao Chen; Xiao-Ping Dong
Journal:  Infect Dis Poverty       Date:  2016-06-02       Impact factor: 4.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.